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Abstract
Background: Infection is a recognised risk factor for Alzheimer’s disease (AD) and can worsen symptoms in
established disease. AD patients have higher rates of infection and are more likely to require hospital admissions
due to infections than individuals without dementia. Infections have also been found to increase the risk of those
over 84 years of age being diagnosed with dementia. However, few studies have investigated immune responses
to infection in AD.
Methods: Here, we investigated the immune responses of the triple transgenic Alzheimer’s disease (3xTg-AD)
mouse model of AD to infection with the parasites Toxoplasma gondii and Trichuris muris. Cytometric bead array,
histology, immunohistochemistry and immunofluorescence were used to evaluate immune responses and the
effects on the brain of acute infection.
Results: 3xTg-AD mice, despite having comparable parasite loads, were more susceptible to infection with more
severe morbidity. A worsened outcome to infection can be linked to an exaggerated immune response. 3xTg-AD
mice had an increased pro-inflammatory response characterised by the production of pro-inflammatory mediators
such as tumour necrosis TNF-α, IL-6, CCL5 and CXCL-1, as well as an increase in immune cell infiltration to the sites
of infection. T cell responses to parasite antigen also showed elevated production of the pro-inflammatory
cytokines TNF-α (10 fold) and IL-6 (twofold). We investigated whether 3xTg-AD mice had a propensity for a more
Th1-dominated response using the T. muris worm infection and showed that akin to T. gondii, there was an
enhanced pro-inflammatory response which was associated with retention of worms in the gut and associated
pathology. Irrespective of whether the infection was one that could infect the brain or cause a local gut
inflammation, 3xTg-AD mice had increased numbers of activated microglia during infection in both the cortex and
the hippocampus.
Conclusions: Our findings suggest that in AD, responses to infection are exaggerated outside of the CNS.
Additionally, the results presented here indicate that both systemic and localised inflammation caused by an
infection exacerbate neuroinflammation in AD.
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Background
Alzheimer’s disease (AD) is a chronic neurodegenerative
disease which affects over 35 million people worldwide [1].
The disease is characterised by the accumulation of Aβ pro-
tein and the deposition of tau neurofibrillary tangles
(NFTs). There are no treatments to stop or reverse the ef-
fects of AD, and most patients die within 3–9 years of diag-
nosis [2]. Infections are a common co-morbidity in
individuals with AD, with higher rates of infection and
more frequent hospital admissions [3–5]. Pneumonia is the
most common cause of death for patients with AD [6], and
infections have been found to increase the risk of those
over 84 years of age being diagnosed with dementia [7].
Over the last decade, a growing body of research has
implicated inflammation in the pathology of AD. Pa-
tients taking non-steroidal anti-inflammatory drugs
(NSAIDs) are significantly less likely to develop AD [8];
several genetic risk factors for AD have been identified
which also have roles within the immune system, such
as the myeloid cell receptor TREM2 [9], and genome-
wide association studies (GWAS) suggest that there is
widespread dysfunction of the immune system in AD
[10]. It is currently unclear how the immune system out-
side of the central nervous system (CNS) is affected in
AD patients or how alterations in the immune system
affect the response of AD patients to an infection. Re-
ports on differences in the immune system of AD pa-
tients are conflicting. Studies have shown increases [11]
and decreases [12] in CD4+ T cells in AD patients. CD8
+ T-cell numbers were increased in several studies [11–
15]; however, other studies found no differences in CD8
+ cells [16, 17]. Studies examining cytokine levels in AD
patients are also conflicting. Increases in interleukin 6
(IL-6), IL-1β and the acute phase protein C-reactive pro-
tein have been reported in the peripheral blood of AD
patients, as well as decreases in tumour necrosis factor
alpha (TNF-α) [18, 19]. However, some studies have not
found differences in peripheral blood and have only seen
differences in AD patients following stimulation. Follow-
ing lipopolysaccharide (LPS) stimulation of whole blood
culture, AD patients had higher levels of IL-1β, TNF-α,
IL-6 and IL-10 [11]. Dysregulation of the immune sys-
tem has also been reported in the triple transgenic Alz-
heimer’s disease (3xTg-AD) mouse model of AD [20],
including increased lymphocyte chemotaxis [21] and in-
creased C-C chemokine receptor 6 (CCR6) expression
outside of the CNS [22]. Additionally, functions of the
immune system deteriorate with age, which is referred
to as immunosenescence. Immunosenescence is charac-
terised by increased susceptibility to infection and prob-
lems with lymphocyte development and function [23].
As AD is predominantly a disease of old age [2], some of
the factors attributed to AD may be due to age-related
immunosenescence.
It is known that systemic inflammation caused by in-
fection can impact the brain. Brains of patients who died
from sepsis have significantly increased levels of micro-
glial activation [24], as do animals injected with lipopoly-
saccharide (LPS) [25]. In AD, infections worsen
symptoms in patients with established disease with the
rate of cognitive decline increased post infection [26,
27]. During AD, microglia are thought to proliferate and
become sensitised to secondary stimuli such as a periph-
eral infection. This process is known as microglia prim-
ing [28]. Given the links between infection and
worsened prognosis in AD, it is important to understand
how systemic and localised infections affect the brain in
AD. To address the immune response in AD pathology,
we looked at how the immune system of a mouse model
of AD responds to systemic and localised infection using
two models of infection—Toxoplasma gondii (T. gondii)
and Trichuris muris (T. muris).
Immune responses to both T. gondii and T. muris have
been studied extensively in mice, so the parasites are
useful tools with which to study the immune response
to infection in AD. T. gondii and T. muris infect via the
oral route, but T. gondii becomes a systemic infection
and forms a lifelong chronic infection in tissues such as
the eyes and central nervous system, including the brain
[29]. In the brain, T. gondii preferentially infects areas af-
fected by AD pathology, such as the hippocampus [30].
T. gondii is typified by a Th1 response. In contrast, T.
muris remains localised to the colon and caecum, and
resistance is associated with a Th2 response [31].
Previous studies have investigated chronic infection
with T. gondii in AD mouse models. In the Tg2576
model, AD mice had higher levels of IL-10 and TFG-β
in the brain 6 months post infection (PI) with the ME49
type II strain of T. gondii, when compared to uninfected
AD mice. Infected AD mice also had reduced Aβ plaque
deposition in the cortex and hippocampus and reduced
learning and memory impairments in the Morris water
maze and Y maze [32]. A second study investigated
chronic T. gondii infection in the 5xFAD model of AD,
also infected with the ME49 type II strain of the parasite.
At 28 days PI, 5xFAD mice had reduced Aβ plaque de-
posits, as well as recruitment of myeloid-derived CCR2hi
Ly6Chi monocytes, CCR2+ Ly6Cint, and CCR2+
Ly6Clow mononuclear cells. Both recruited cell types
were shown to have an increase of Aβ phagocytosis in
vivo, which may explain the decrease in Aβ plaque de-
posits in this study [33]. However, no study has previ-
ously investigated the effects of acute T. gondii infection
on neuroinflammation in AD, and no studies have previ-
ously investigated infection with the parasite T. muris in
AD mouse models.
In this study, we investigated the effects of infection
with the parasites T. gondii and T. muris in the 3xTg-AD
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mouse model of AD. We found that 3xTg-AD mice have
increased production of pro-inflammatory mediators
such as TNF-α, IL-6, C-C chemokine ligand 5 (CCL5)
and chemokine CXC ligand 1 (CXCL-1), as well as in-
creased immune cell infiltration. Following T. gondii in-
fection, T cell responses to parasite antigen in the spleen
also showed elevated production of the pro-
inflammatory cytokines TNF-α and IL-6. Irrespective of
whether the infection was one that could infect the brain
or cause local gut inflammation, 3xTg-AD mice had in-
creased numbers of activated microglia during infection
in both the cortex and the hippocampus.
Methods
Animals
3xTg-AD and background strain wild-type non-
transgenic (Non-Tg) (C57BL6/129sv) male mice were
bred from in house colonies, established from mice ori-
ginally supplied by Frank LaFerla and Salvadore Oddo
(University of California-Irvine, CA). For each parasite,
we assessed specific immune responses well known to
each infection model. In the T. gondii infection, both 5–
6-month and 11–12-month-old mice were used, to in-
vestigate the effects of age on the response to infection
in AD. In the T. muris infection, 6-month-old mice were
used to allow comparisons with the responses of 5–6-
month-old mice to T. gondii infection. Mice were
housed in standard housing conditions (20 ± 2 °C, hu-
midity 55 ± 5%, 12-h light cycle with lights on at 07:00).
Mice were given ad-libitum access to food and water.
All procedures were performed under appropriate per-
sonal and project licences and in accordance with the
Home Office (Animals) Scientific Procedures Act (1986).
Animals were housed as non-littermate controls of 3–6
animals per cage. Cages were randomly allocated into
treatment groups.
Infections
In the first set of experiments, mice were infected by
oral gavage with 1 × 104 tachyzoites of the type II T. gon-
dii strain expressing the dimeric tomato red fluorescence
protein [34]. Tachyzoites were passaged through human
foreskin fibroblast cells (European collection of cell cul-
ture, Porton Down, UK) before infection. Mice were
sacrificed at 5, 7 and 9 days PI. Day 5 PI was chosen to
examine small intestine pathology, day 7 PI as the likely
peak of systemic infection, and day 9 PI as the parasite
would be likely to have reached the brain at this time
point. The number of animals per group were as follows:
5–6-month-old Non-Tg mice (5 Naïve mice, 5 mice
culled at day 5 PI, 7 mice at day 7 PI and 6 mice at day
9 PI), 5–6-month-old 3xTg-AD mice (5 Naïve mice, 5
mice culled at day 5 PI, 7 at day 7 PI and 4 at day 9 PI),
11–12-month-old Non-Tg mice (6 Naïve mice, 5 culled
at day 7 PI and 4 at day 9 PI) and 11–12-month-old
3xTg-AD mice (3 Naïve, 4 culled at day 7 PI and 3 at
day 9 PI). In a second experiment, 10-month-old mice
were infected by intraperitoneal (IP) injection with 1 ×
104 tachyzoites of the same strain of T. gondii. The Y
maze behavioural test was carried out at 5 days PI; the
open field behavioural test was carried out at 6 days PI
and culled at day 9 PI. In both experiments, animals
were culled using a rising concentration of carbon diox-
ide (CO2). All animals were infected in the morning be-
tween 9 and 11 a.m. on day 0 PI. Mice were weighed
and checked daily for signs of ill health throughout in-
fection. No animals lost more than 10% of their original
body weight during the infection.
In the third set of experiments, mice were infected
with approximately 40 viable eggs of the E strain of T.
muris by oral gavage and killed at 35 days PI. Mainten-
ance of the T. muris life cycle and production of excre-
tory/secretory (E/S) antigen were carried out as
described previously [35]. Mice which are resistant to T.
muris typically expel the parasite between 11–28 days
PI. In susceptible mice, which are unable to expel the
parasite, T. muris worms can usually be detected from
35 days PI. Each experimental group contained 4 ani-
mals, and all animals were 6 months of age. Animals
were culled using a rising concentration of CO2. Imme-
diately post-mortem, the caecum was cut and washed
out with water to flush out the faecal contents, and the
numbers of T. muris worms were counted at ×4 magnifi-
cation using a dissection microscope. Mice were weighed
daily and checked daily for signs of ill health for the first
2 weeks of infection, after which animals were checked
every few days. No animals lost more than 10% of their
original body weight during the infection.
Splenocyte and MLN cell culture and cytokine analysis
Spleens were taken at autopsy and strained through a
100-μm cell strainer (Fisher Scientific, Loughborough,
UK), and red blood cells were removed by treatment
with a red blood cell lysis buffer (Sigma Aldrich, MO,
USA). Cells from T. gondii-infected mice were plated at
1 × 106 cells/well and incubated in the presence of STAg
(soluble tachyzoite antigen) (25 μg/ml) for 24 h or ConA
(2.5 μg/ml) for 72 h. STAg was produced from cultured
tachyzoites, freeze thawed in liquid nitrogen and filtered.
Single-cell suspensions were prepared from mesenteric
lymph nodes (MLNs) from T. muris-infected mice and
plated at 1 × 106 cells/well of a 96-well plate. Cells were
incubated with E/S antigen (50 μg/ml) for 48 h or ConA
(2.5 μg/ml) for 72 h. All cells were incubated at 37 °C,
5% CO2 and after incubation supernatants were har-
vested and stored at −80 °C. Levels of IL-10, 1 L-13, IL-
4, IL-6, IL-1β, IL-1α, interferon gamma (IFN-γ), TNF-α,
CXCL-1, CCL5 and CCL2 were determined using a
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custom cytometric bead array (CBA) according to the
manufacturer’s instructions (BD Biosciences, Oxford,
UK), and plates were read using a MACSQuant Analyser
(Miltenyi Biotec, Cologne, Germany). Analysis was car-
ried out using FCAP Array™ Software (BD Biosciences).
Histology
Liver and small intestine samples from T. gondii-infected
mice and colon samples from T. muris-infected mice
were fixed in neutral-buffered formalin for 24 h, proc-
essed and embedded in paraffin wax. Five-μm sections
were dewaxed, rehydrated and stained using a standard
haematoxylin and eosin staining method. In liver sam-
ples, inflammatory foci were counted; an average was
taken for each mouse of 3 fields of view at 10× magnifi-
cation. In small intestine samples, the length of 20 villi
were measured and averaged per mouse at 10× magnifi-
cation. Liver and small intestine measurements were car-
ried out using Pannoramic Viewer software (3D
HISTECH, Budapest, Hungary). In colon samples, the
length of 20 crypts was measured using ImageJ (National
Institutes of Health, MD, USA) and averaged per mouse
at 10× magnification. All slides were measured and
counted blind in a randomised order.
Immunohistochemistry
Colon samples from T. muris-infected mice were flash
frozen in optimal cutting temperature compound (OCT;
Thermo Fisher Scientific, Runcorn, UK) and stored at
−80 °C. Five-μm sections were cut using a cryostat (Leica
Biosystems, Milton Keynes, UK). Sections were incubated
with primary antibodies to CD45 5 μg/ml (Bio-Rad, Lang-
ford, UK) or F4/80 5 μg/ml (Bio-Rad, Langford, UK).
Slides were incubated with avidin and biotinylated horse-
radish peroxidase macromolecular complex kit (ABC;
Vector Laboratories, Peterborough, UK), then developed
using 3,3’-diaminobenzidine (DAB; Vector Laboratories,
Peterborough, UK). Slides were then washed and counter-
stained with HaemQS (Vector Laboratories, Peterbor-
ough, UK). Slides were imaged using an Olympus BX51
upright microscope using ×10 objective and captured
using a Coolsnap ES camera (Photometrics, Tucson, USA)
through MetaVue Software (Molecular Devices, Sunny-
vale, USA). CD45+ or F4/80+ cells were counted for 20
crypts from three disparate areas in the colon of each
mouse and then averaged. All slides were measured and
counted blind in a randomised order.
Immunofluorescence
Immunohistochemistry was performed on free-floating
brain sections. Non-specific binding was blocked by treat-
ment with 2% normal donkey serum (NDS) (Vector La-
boratories, Peterborough, UK) for 1 h at room temperature.
Sections were incubated overnight in antibody diluent
(0.1 M PBS, 0.1% Triton, 2% NDS) using the following pri-
mary antibodies: rabbit anti-mouse Iba1 2 μg/ml (Wako
Chemicals, Düsseldorf, Germany) and goat anti-mouse Ds-
Red 1 μg/ml (Stratech, Newmarket, UK). Antigens were
visualised with the appropriate (Alexa Fluor 488 1 μg/ml
Molecular Probes or Alex Fluor 594 1 μg/ml Santa Cruz
Biotechnology, Santa Cruz, USA) secondary donkey anti-
sera for 2 h at room temperature. Sections were mounted
onto gelatin-coated slides, dehydrated and coverslipped
using ProLong Gold Antifade reagent (Molecular Probes,
Thermo Fisher Scientific, Runcorn, UK). Images were col-
lected using an Olympus BX51 upright microscope using
×10 objective and captured using a Coolsnap ES camera
(Photometrics, Tucson, USA) through MetaVue Software
(Molecular Devices, Sunnyvale, USA). Specific band pass
filters for DAPI, FITC and Texas red were used to prevent
bleed through from one channel to the next. Images were
processed and analysed using ImageJ (National Institutes of
Health, MD, USA).
Activated microglia were identified as showing (1) in-
creased Iba1 immunopositivity, (2) enlarged and/or
amoeboid cell body and (3) complete or partial loss of thin,
elongated processes. Round-shaped, small Iba1-positive
cells with leucocyte morphology were not counted. Acti-
vated microglia were counted through the cortex and the
hippocampus. In the cortex for each animal, images were
taken from the top, middle and bottom of the cortex from
three brain sections from the front, middle and back of the
brain. In the hippocampus, averages were taken from CA1,
CA2, CA3 and the dentate gyrus (DG) of sections from the
front, middle and back of the brain. All slides were mea-
sured and counted blind in a randomised order.
Statistics
All data analysis was carried out on blinded and rando-
mised samples. Power calculations were carried out
using the Statistical Solutions Power and Sample Size
Calculator (Statistical Solutions, WI, USA) using previ-
ous data from our group and calculated for an effect size
of 80%. All statistical analyses were carried out using
GraphPad Prism version 6.04 (GraphPad Software, San
Diego, USA). For two groups, parametric data were ana-
lysed using Student’s t test, and for data with unequal
variances, Welch’s correction was applied. All other stat-
istical analyses were performed using two-way analysis
of variance with Tukey’s multiple comparison test. All
data are expressed as mean ± standard error of the mean
(SEM). P values of <0.05 were considered significant.
Results
Increased inflammation in 3xTg-AD mice following infec-
tion with T. gondii
In the liver, numbers of inflammatory foci were signifi-
cantly higher in infected 3xTg-AD mice than in infected
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Non-Tg mice at both 7 days (Fig. 1b; P ≤ 0.05) and
9 days (Fig. 1c; P ≤ 0.01) PI. Significant increases in
inflammatory foci were seen in both 5–6-month-old
and 11–12-month-old 3xTg-AD mice compared with
controls. No inflammatory foci were seen in either
Non-Tg or 3xTg-AD Naïve mice at either age (data not
shown). T. gondii infection is also associated with a transi-
ent ileitis in the small intestine, another major site of
acute infection. Although we saw evidence of ileitis post
infection, there was no difference in the response between
3xTg-AD and Non-Tg mice (data not shown).
The immune response to T. gondii infection is associ-
ated with splenocyte cell proliferation as one of the sites
of immune activation. Splenocyte numbers were not
seen to be significantly different between infected 5–6-
month-old Non-Tg mice and 3xTg-AD mice (Fig. 1d),
but in 11–12-month-old mice, spleen cell numbers were
significantly increased (P ≤ 0.05) in infected 3xTg-AD
mice compared to naïve Non-Tg mice (Fig. 1e).
3xTg-AD mice have an increased pro-inflammatory
response following infection with T. gondii
We next wanted to determine whether the increase in
immune cells seen in 3xTg-AD mice following T. gondii
infection was also associated with increased cytokine
and chemokine secretion. Infection with T. gondii trig-
gers a rapid Th1 cell-mediated response, which peaks at
around day 7 PI. Parasite specific responses were ana-
lysed by stimulating splenocytes at 7 days PI with STAg.
Significantly increased levels of the cytokine TNF-α (P ≤
0.001) and the chemokines CCL5 (P ≤ 0.01) and CXCL-1
(P ≤ 0.0001) were found in infected 3xTg-AD mice com-
pared to infected Non-Tg mice. This trend for elevated
levels of pro-inflammatory cytokines following STAg
stimulation was consistent across two additional inde-
pendent T. gondii infection time courses we carried out
in 3xTg-AD mice (data not shown). Interestingly, TNF-α
levels were significantly lower in infected 11–12-month-
old 3xTg-AD mice than in infected 5–6-month-old
Fig. 1 Inflammatory cell infiltration following T. gondii infection in 3xTg-AD mice. Mice were infected with 1 × 104 tachyzoites of T. gondii by oral gavage.
a Representative images of inflammatory foci infiltration in the livers of Non-Tg and 3xTg-AD mice post infection. Numbers of inflammatory foci in the liver
were analysed at day 7 (b) and day 9 (c) post infection. Splenocyte numbers were counted in d 5–6-month-old mice and e 11–12-month-old mice at
7 days post infection. *P≤ 0.05; **P≤ 0.01. All data are shown as mean ± SEM
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3xTg-AD mice (P ≤ 0.01) (Fig. 2). STAg stimulation was
also carried out at day 9 PI; however, only low levels of
cytokine expression were observed at this time point,
and no differences were seen between 3xTg-AD and
Non-Tg mice (data not shown).
Increased microglial activation in 3xTg-AD mice following
infection with T. gondii
The possibility that elevated serum and splenic cytokine
responses would be associated with greater microglial
activation in the brain was explored using immunohisto-
chemistry. Iba1 staining was used to identify activated
microglia, although it may also have detected some local
or infiltrating macrophages. At day 7 PI, which corre-
sponds to the time when it was unlikely for parasite to
be present in the brain, infected 5–6-month-old 3xTg-
AD mice had significantly more activated microglia in
the cortex than naïve Non-Tg mice (P ≤ 0.01; Fig. 3a). At
11–12 months of age at day 7 PI, infected 3xTg-AD also
had significantly higher numbers of activated microglia
in the cortex compared with Non-Tg mice (P ≤ 0.05;
Fig. 3b).
At day 9 PI, a time point in which there should be
parasite present in the brain, microglial activation in-
creased significantly in infected 3xTg-AD mice in both
the cortex (P ≤ 0.05) (Fig. 4a) and the hippocampus (P ≤
0.001) (Fig. 4c) of in 5–6-month-old mice. Infected
Non-Tg mice had increased microglial activation in
the hippocampus (P ≤ 0.05) (Fig. 4c) but not in the
cortex (Fig. 4a), and the increase in the hippocampus
was smaller than that seen in 3xTg-AD mice. At 11–
12 months of age, microglial activation was signifi-
cantly higher in infected 3xTg-AD mice compared to
non-infected 3xTg-AD mice in both the cortex (P ≤
0.01) and the hippocampus (P ≤ 0.05). In contrast, at
11–12 months, no significant increase was seen in the
numbers of activated microglia in infected Non-Tg
compared to non-infected Non-Tg mice (Fig. 4b, d).
The possibility that microglial activation correlated
with parasite burden or presence of parasite in micro-
glial areas was investigated. At day 7, only very low
levels of parasites were detected in the brains of infected
mice, and the numbers of parasites detected in the brain
increased at day 9 PI (for qPCR see also Additional file
1: Figure S1). There was no significant difference in the
amount of T. gondii parasites in the brains of 3xTg-AD
to Non-Tg mice at day 7 or day 9 PI in either the cortex
(Fig. 5b) or the hippocampus (Fig. 5c). Naïve mice had
no T. gondii parasites in the brain. Parasites at day 9
were not found to be localised to activated microglia.
This data suggests that the enhanced microglial activa-
tion is not due to increased parasite load in the brains of
3xTg mice. The possibility that the microglial activation
was due to enhanced local brain cytokines was next in-
vestigated by qPCR on the brains 9 days PI with T. gon-
dii. No significant differences in the expression of IL-1α,
IL-1β or TNF-α were seen in the brains of infected
3xTg-AD mice compared to naïve 3xTg-AD, naïve Non-
Tg or infected Non-Tg mice. Levels of IFN-γ and IL-12
were too low to detect (see Additional file 2: Figure S2).
Fig. 2 Cytokine and chemokine expression after STAg stimulation of splenocytes following infection with T. gondii. Splenocytes from day 7 PI
were isolated and stimulated with STAg (25 μg/ml) for 24 h, and cytokine and chemokine levels were measured using a CBA. **P ≤ 0.01; ***P ≤
0.001; ****P≤ 0.0001. All data are shown as mean ± SEM
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The possibility that infection could impact behaviour
was also assessed. No significant differences were found
between infected Non-Tg and infected 3xTg-AD animals
in behavioural tests (see Additional file 3: Figure S3).
Elevated pro-inflammatory responses in 3xTg-AD mice
after T. muris infection
3xTg-AD mice were infected with T. muris to investigate
whether exaggerated immune responses were also seen
in a localised infection that does not infect the brain.
During acute T. muris infection, the major site of infec-
tion and inflammatory cell infiltration is the colon, and
thus, we determined numbers of CD45 positive cells in
the colon. CD45+ cell levels were increased following in-
fection, with a larger increase in 3xTg-AD mice (P ≤
0.0001) compared to Non-Tg animals (P ≤ 0.05) (Fig. 6a,
c). We also measured the number of F4/80+ macro-
phages in the colon following infection with T. muris.
Significantly higher numbers of macrophages were seen
in both Non-Tg and 3xTg-AD mice following infection;
however, the increase following infection was larger in
3xTg-AD mice than in Non-Tg mice, with a significant
interaction effect seen between genotype and infection
(P ≤ 0.01) (Fig. 6b, d). T. muris infection is associated
with altered crypt architecture in the colon; however, we
saw no differences in crypt length between infected
Non-Tg and 3xTg-AD mice (data not shown).
To determine the specific response to T. muris, MLNs
were stimulated with the T. muris specific antigen E/S.
Following E/S stimulation, infected 3xTg-AD mice pro-
duced significantly larger amounts of the cytokines IL-6
(P ≤ 0.01), IL-10 (P ≤ 0.05) and TNF-α (P ≤ 0.01) than
naïve 3xTg-AD mice and significantly larger amounts of
IL-6 (P ≤ 0.05) and IL-10 (P ≤ 0.05) than infected Non-Tg
mice. No differences were seen between naïve Non-Tg
and infected Non-Tg mice following E/S stimulation of
MLNs (Fig. 7a). Non-Tg mice were able to expel the
parasite, with the exception of one mouse that had a sin-
gle worm remaining in the colon. 3xTg-AD mice were
unable to expel the parasite and still had worms in their
gut at day 35 suggesting they had developed a chronic
infection (P ≤ 0.01; Fig. 7b).
Fig. 3 Microglial activation following T. gondii infection in 3xTg-AD mice 7 days PI. Activated microglia were identified by increased Iba1 positivity,
thickened processes and irregular cell bodies. Microglial activation is shown in the cortex of a 5–6-month-old mice and b 11–12-month-old mice
at day 7 PI. c Iba1 staining in the cortex of naïve and infected mice at day 7 PI; insets show representative images from each group. Scale bars
show 100 μm. *P < 0.05; **P≤ 0.01; ***P≤ 0.001. Secondary comparisons are indicated by ##P ≤ 0.01 above groups which differ significantly from
one another. All data are shown as mean ± SEM
Montacute et al. Journal of Neuroinflammation  (2017) 14:50 Page 7 of 13
Microglial activation was also assessed following infec-
tion with T. muris; significant increases in activated
microglia were seen in both 3xTg-AD mice and Non-Tg
mice in both the cortex (P ≤ 0.01) (Fig. 8b) and the
hippocampus (P ≤ 0.05) (Fig. 8c) relative to naïve animals
following infection. The increase in microglial activation
following infection was greater in 3xTg-AD mice than in
Non-Tg mice, in the cortex (P ≤ 0.01) and the hippocam-
pus (P ≤ 0.01).
Discussion
Infection is a common co-morbidity in AD, which is
thought to impact the quality and length of life of AD
patients. AD patients are more likely to get an infection
[36], have worsened symptoms from infection and more
often need hospitalisation from conditions such as pneu-
monia [5, 37]. This study is the first to show that in an
AD mouse model, regardless of whether the infection
reaches the brain, the immune system’s response to an
infection is altered outside of the brain. Outside of the
brain, 3xTg-AD mice had increased immune cell infiltra-
tion and higher levels of pro-inflammatory cytokine and
chemokine production following infection. Additionally,
this study demonstrated that in 3xTg-AD mice, a local
distant infection is also linked to higher levels of inflam-
mation in the brain, with increased microglial activation
following infection. There are not currently any drugs
available which can stop or reverse the effects of AD.
However, if infections are worsening AD outcome, better
prevention and/or treatment of infection could improve
the quality of life of AD patients.
This study demonstrated a generalised pro-inflammatory
response in 3xTg-AD mice to infection, resulting in wors-
ened pathology and altered immunity. Consistent with our
findings, previous work has found several differences in the
immune systems of 3xTg-AD mice compared to Non-Tg
animals. Naïve 3xTg-AD mice have been previously shown
to have abnormal enlargement of the spleen and liver, an
Fig. 4 Increased microglial activation following T. gondii infection in 3xTg-AD mice. Activated microglia were identified by increased Iba1 positivity,
thickened processes and irregular cell bodies. Microglial activation is shown in the cortex of 5–6-month-old a and 11–12-month-old b mice at day 9
PI, and the hippocampus of 5–6-month-old c and 11–12-month-old d mice at day 9 PI. e Iba1 staining in the cortex of naïve and infected mice at day
9 PI; insets show representative images from each group. Scale bars show 100 μm. *P < 0.05; **P≤ 0.01; ***P≤ 0.001. Secondary comparisons are
indicated by #P < 0.05 or ##P≤ 0.01 above groups which differ significantly from one another. All data are shown as mean ± SEM
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Fig. 5 Parasite burden in the brain following T. gondii infection. a Representative images of T. gondii and Iba1 staining in the cortex of Non-Tg and
3xTg-AD mice at day 9 PI. Parasite burden in the cortex in infected mice in the b cortex and the c hippocampus. All data are shown as mean ± SEM
Fig. 6 Exaggerated inflammatory cell responses following infection with T. muris in 3xTg-AD mice. At 35 days PI colon sections were stained for
a CD45 and b F4/80 and the average 20 crypts per area counted over three disparate areas for c CD45 and d F4/80. Images show representative
staining in 3xTg-AD and Non-Tg mice. *P < 0.05; **P≤ 0.01; ***P≤ 0.001. All data are shown as mean ± SEM
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increased number of double-negative CD4−CD8− spleno-
cytes [20], increased lymphocyte chemotaxis [21] and in-
creased C-C chemokine receptor 6 (CCR6) expression
outside of the CNS [22]. It is not clear how altered im-
mune responses to infection outside of the CNS in AD
mice relate to immune responses in AD patients although
differences in the immune system are known to occur in
AD patients. Studies in human AD patients have seen in-
creased levels of TNF-α in serum from patients with severe
AD [12]. AD patients are more likely to be hospitalised for
infections including pneumonia [3], gastroenteritis [4] and
urinary tract infections (UTIs) [5] than the general popula-
tion, which may be due to exaggerated immune responses
to infection. Additionally, following lipopolysaccharide
(LPS) stimulation of whole blood from AD patients, higher
levels of IL-1β, TNF, IL-6, and IL-10 have been reported
[11]. AD patients with periodontitis have higher levels of
serum IL-6 and TNF-α than uninfected controls [38]. The
elevated pro-inflammatory responses seen in AD patients
are similar to our observations in 3xTg-AD mice, suggesting
that our findings are likely to be relevant to AD patients.
Previous work in 3xTg-AD mice has found elevated
levels of TNF-α in the entorhinal cortex of AD mice
[39], but we found no change in the levels of any of the
cytokines measured that were found in infected or naive
mice. However, in this study, cytokine levels were mea-
sured in the whole brain; therefore, any localised
changes would not have been detected. In infection with
the parasite T. gondii, microglial activation occurred
from day 7 PI when we saw only very low levels of para-
site in the brain; it is likely to be due to inflammation
outside of the CNS. Furthermore, microglial activation
was observed following T. muris infection, a parasite
model which does not infect the brain and causes a
localised infection in the large intestine. Microglia are
thought to be primed by ongoing pathology in the brain
during AD and to be activated following immune chal-
lenge outside of the CNS [28]. In 3xTg-AD mice, infec-
tion with the mouse hepatitis virus by intracranial
injection increased levels of microglial activation and in-
filtration of macrophages and T cells. In keeping with
our findings, peripheral administration of LPS has been
shown to result in microglial activation in the 3xTg-AD
mouse model [40]. However, LPS administration is a
simplified model for an inflammatory stimulus as it will
trigger a restricted repertoire of responses. Additionally,
the doses of LPS administered to mice are much higher
than doses which, in humans, would cause septic shock,
so the use of LPS is unlikely to be a good model for the
impacts of a systemic infection on human disease [41].
Here, we have shown that microglial activation occurs
during common and well-characterised infections. Our
findings are similar to observations in patients. AD pa-
tients who have suffered from an infection also have a
Fig. 7 Responses in 3xTg-AD mice to infection with the nematode parasite T. muris. a 6-month-old mice were infected with 40 viable eggs of the E strain
of T. muris (low dose) and sacrificed at 35 days PI. MLNs from T. muris-infected mice were plated 1 × 106 cells/well of a 96-well plate and stimulated with
E/S antigen (50 μg/ml) for 48 h; cytokine and chemokine levels were measured by CBA. b T. muris worm burden was enumerated. Scale bars show
100 μm. *P< 0.05; **P≤ 0.01; ***P≤ 0.001. All data are shown as mean ± SEM
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greater rate of cognitive decline than patients without
infection, a difference linked to increased levels of serum
IL-1β [26]. A decrease in cognitive decline in AD patients
following systemic inflammation has been seen to last at
least 6 months after the event and has also been linked to
higher serum levels of TNF [27].
T. gondii is a relevant infection in AD patients as it is
a common infection in developed countries where AD is
most common, with infection rates as high as 80% in
countries such as France and Germany and rates of 10–
20% in the USA although due to the lack of screening
for T. gondii in the UK and USA, it is likely that infec-
tion rates will be higher [42]. Increased seroprevalance
of T. gondii infection was found in individuals with AD,
but whether this represents a risk factor for AD develop-
ment or is associated with changes in pathology has not
been determined [43]. In mouse studies, chronic infec-
tion with T. gondii has been suggested to be beneficial
with reduced plaque burden and higher levels of anti-
inflammatory cytokines [32]. T. gondii is a lifelong infec-
tion but can be acquired for the first time at any stage in
life. In our study, the 3xTg-AD mice were unusually sus-
ceptible to acute infection, and thus, we could not inves-
tigate effects of chronic infection, but notably, several of
the findings in acute infection reflect results found fol-
lowing chronic infection in AD. Previous work on
chronic T. gondii infection in the Tg2576 AD mouse
model found that levels of the pro-inflammatory cyto-
kine IFN-γ remained unchanged in the brain following
infection [32]. Similarly, we reported unchanged levels
of the pro-inflammatory cytokines IL-1α, IL-1β and
TNF-α in the brain following acute infection with T.
gondii even at time points correlating with parasite pres-
ence in the brain. Additionally, following chronic T. gon-
dii infection in the 5xFAD mouse model, increased Iba1
positive staining was noted in infected mice [33] and also
we saw increased microglial activation acute infection.
Functions of the immune system are known to de-
teriorate with age, which is referred to as immunose-
nescence. AD is predominantly a disease of old age
[2]; therefore, some of the factors attributed to AD
may be due to age-related immunosenescence. No
previous studies in animals or humans have investi-
gated how immune responses in 3xTg-AD mice alter
with age. Our findings suggest that some specific as-
pects of the immune response may be dampened with
age in these animals, as levels of TNF-α in 3xTg-AD
mice following infection were significantly lower in
Fig. 8 Increased microglial activation following T. muris infection in 3xTg-AD mice. a Brains were stained with Iba1, and activated microglia were
identified. Images show representative staining in the cortex of 3xTg-AD and Non-Tg mice. Enumeration of activated microglia in b the cortex
and c the hippocampus of 6-month-old mice following infection with T. muris
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11–12-month-old mice compared to 5–6-month-old
animals, although still higher than in WT animals of
the same age. However, increased immune cell infil-
tration was seen in AD mice irrespective of age. Our
data therefore suggest that despite increased age,
there is not widespread immunosenescence in older
mice. It may be that in mice older than the 11–12-
month-old animals used in this study, we see this effect
drop off, and this might be interesting to be addressed in
future studies.
Conclusions
The data presented here suggests that in AD, responses
to infection are exaggerated outside of the CNS and that
both systemic and localised inflammation caused by an
infection increases neuroinflammation in AD and thus
have implications for the management of AD.
Additional files
Additional file 1: Figure S1. 11-month-old mice were infected with
1 × 104 tachyzoites of the PRU strain of T. gondii by oral gavage and
culled at day 9 PI. One hemisphere of the brain was homogenised, RNA
extracted and qPCR carried out for SAG-1 (tachyzoites) and Cysts. Data
analysed by two-way ANOVA with Tukey’s multiple comparisons test. All
data are shown as mean ± SEM. (TIF 17 kb)
Additional file 2: Figure S2. Cytokine levels in the brain at day 9 PI with
T. gondii in 3xTg-AD mice. Mice were infected with 1 × 104 tachyzoites of T.
gondii by oral gavage. One hemisphere of the brain was homogenised, RNA
extracted and qPCR carried out on (A) 5–6-month-old and (B) 11–12-
month-old animals. Data analysed by two-way ANOVA with Tukey’s multiple
comparison test. All data are shown as mean ± SEM. (TIF 101 kb)
Additional file 3: Figure S3. 10-month-old 3xTg-AD mice were in-
fected with 1 × 104 tachyzoites of T. gondii by IP injection. Open field be-
havioural testing was carried out 6 days PI. During open field, the (A)
number of line crossings, (B) time spent mobile, (C) number of rears and
(D) number of defecations during the test were measured. The Y-maze
behavioural test was carried out 5 days PI. (E) Percentage alternations
and (F) the number of arm entries in the Y-maze were measured. Data
analysed by two-way ANOVA with Tukey’s multiple comparisons test, *p
< 0.05; **p < 0.01. All data are shown as mean ± SEM. (TIF 133 kb)
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